Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE
|
|
- Harold York
- 6 years ago
- Views:
Transcription
1 LA APLA 1 3 ACA Anti-ß2-GP I 2 45 Thrombophilia Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC GASCO Atlanta Sept 8 th, 2017 Disclosures Conflicts of interest: NONE Off-label product use discussion: NONE 1
2 Topics Introduction Whom to Test What to Test When to Test My Choosing Wisely Suggestions Introduction 2
3 Recurrence Triangle 3 months Long-term VTE due to major transient risk factor Woman with VTE on hormones Non-major transient risk factor Woman with unprovoked VTE DVT PE Man with unprovoked VTE DVT PE - D-dimer + Strong Thrombophilia [Choosing Wisely ; Hicks LK, et al. Hematology Am Soc Hematol Educ Program. 2014;2014: ] ACCP, AHA, ISTH, BJH 3
4 Strong Thrombophilias 1. APLA syndrome 2. Antithrombin deficiency 3. Protein C deficiency 4. Protein S deficiency 5. Homozygous factor V Leiden 6. Homozygous II20210 mutation 7. Heterozygous FVL plus heterozygous II20210 Yes yes / no unknown yes / no [Segal J et al. JAMA 2009; 301: ] [Lijfering WM et al. Circulation 2010;121: ] [Garcia D et al. Blood 2013;122: ] Recurrence Triangle Cumulative VTE Recurrence Rate 1 year 5 years 3 months Long-term VTE due to major transient risk factor Woman with VTE on hormones Non-major transient risk factor Woman with unprovoked VTE DVT PE Man with unprovoked VTE DVT PE 1 % 3 % 6 % * 5 % 15 % 10 % 30 % [Kearon C et al. Blood 2014;123: ] *[Douketis J et al. BMJ 2011;342:d813] 4
5 Downsides of Thrombophilia Testing Take-home point 1. Don t over-focus on the thrombophilia Clinic Patient 39 year old woman Proximal arm DVT and PE 4/2016 VTE risk factors: (a) hetero FV Leiden, (b) hetero II20210 mutation. FH: Parents with VTE. Neither one of them has factor V or factor II. 5
6 Clinic Patient Mother Father Downsides of Thrombophilia Testing 1. Don t over-focus on the thrombophilia 2. Caveat: Wrong test ordered 3. Caveat: Misinterpretation of tests 6
7 Decision Making Based on Thrombophilia 62 year old proximal leg DVT 3 weeks after hip replacement surgery APLA testing positive = life-long anticoagulation Downsides of Thrombophilia Testing 1. Don t over-focus on the thrombophilia 2. Caveat: Wrong test is ordered 3. Caveat: Misinterpretation of tests 4. Caveat: Wrong/questionable decision making based on test result 7
8 Cost $ $ $ $ $ $ $ 2, Cost $
9 Downsides of Thrombophilia Testing 1. Don t over-focus on the thrombophilia 2. Caveat: Wrong test is ordered 3. Caveat: Misinterpretation of tests 4. Caveat: Wrong decision making based on test result 5. Be aware of cost of testing What to Test? Whom to Test? 9
10 Inherited and Acquired Thrombophilias Most common Classics Acquired Others Factor V Leiden Prothrombin Protein C deficiency Protein S deficiency Antithrombin deficiency Antiphospholipid antibodies (ACA, LA, anti-β 2 -GPI) Homocysteine, MTHFR Fibrinogen, factor VIII, IX, XI PAI-1, tpa levels and polymorphisms CBC, CD55/59, JAK-2 + CALR Whom to Test Controversial Guideline in development: ASH 2015, ongoing Terminology used: testing can be considered benefit of testing unclear lack of evidence that testing impacts clinical outcomes 10
11 Whom to Test for Thrombophilia? Everybody Any pt Any pt with Young pt Young pt Nobody with VTE spontan. VTE with FHx Ultra-liberal Nihilist In Whom I Consider Testing DVT/PE, intermediate risk recurrence VTE in unusual locations, unprovoked Arterial thrombosis, unexplained VTE: Patient requests testing Family members (if strong thrombophilia in index pt) No Pregnancy loss(es), unexplained 11
12 Recurrence Triangle 3 months Long-term VTE due to major transient risk factor Woman with VTE on hormones Non-major transient risk factor Woman with unprovoked VTE DVT PE Man with unprovoked VTE DVT PE - D-dimer + Strong Thrombophilia [Choosing Wisely ; Hicks LK, et al. Hematology Am Soc Hematol Educ Program. 2014;2014: ] ACCP, AHA, ISTH, BJH Recurrence Triangle In VTE patients: In intermediate risk-of-recurrence patients I consider testing 12
13 Risk of 1 st VTE with thrombophilias Relative risk increase for first VTE No thrombophilia Reference group II20210, hetero 3.8 (95% CI ) FVL, heterozygous 4.9 (95% CI ) II20210, homozygous Insufficient data FVL, homozygous 18 (95% CI ) Hetero II20210 PLUS 20 (95% CI ) hetero FVL Protein S deficiency 30.6 (95% CI ) Protein C deficiency 24.1 (95% CI ) Antithrombin deficiency 28.2 (95% CI ) [Moll S. J Thromb Thrombolys 2015; ;39(3):367-78] Risk of Recurrent VTE with Thrombophilias 1 II20210, hetero: 1.45 FVL, hetero: 1.56 (95% CI ) (95% CI ) [Segal J et al. JAMA 2009; 301: ] 2 FVL, homo: 2.65 (95 % CI ) FVL, homo: 1.2 (95 % CI ) [Segal J et al. JAMA 2009; 301: ; meta-analysis] [Lijfering WM et al. Circulation 2010;121: ] 3 FVL + II2010: 4.81 (95 % CI ) FVL + II2010: 1.0 (95 % CI ) [Segal J et al. JAMA 2009; 301: ; meta-analysis] [Lijfering WM et al. Circulation 2010;121: ] 4 II20210, homo: insufficient data 13
14 Risk of Recurrent VTE with Thrombophilias 5 Protein C Protein S Antithrombin 2.8 (95 % CI ) [Lijfering WM et al. Circulation 2010;121: ] 6 APLA: 1.41 ACA: 1.53 LA: 2.83 (95 % CI ) (95 % CI ) (95 % CI ) [Garcia D et al. Blood 2013;122: ] APLA syndrome: 2.0 [Kearon C et al; Chest 2012;141:e419S-494S] Protein C, S and Antithrombin Deficiency How do you test? C, S, AT activity free S antigen >100 mutations Acquired deficiency: Liver disease (C, S, AT) How do you treat? Consider AT concentrate Severe neonatal C deficiency: protein C concentrate Warfarin therapy (C, S) Estrogens, pregnancy (S) Inflammatory diseases (S) Heparin therapy (AT) Acute thrombosis (S, AT) 14
15 Antiphospholipid Antibodies APLA I) Antibody test (ELISA) LA ACA anticardiolipin anti-ß2-glycoprotein I antiphosphatidylserine antiphosphatidylcholine antiphosphatidylethanolamine Anti-ß2-GP I II) Functional test lupus anticoagulant (inhibitor) [Sapporo criteria: Miyakis S. J Thromb Haemost. 2006;4: ] APLA: Sapporo/Sydney Criteria Updated Sapporo Criteria for APS (2006): Clinical criteria: Vascular thrombosis Pregnancy morbidity Laboratory criteria*: Anticardiolipin antibodies (IgG or IgM) (medium or high titer: >40 GPL/MPL or >99th percentile) Anti-β 2 -glycoprotein I antibodies (IgG or IgM) (>99th percentile) LA *2 or more occasions, >12 wks apart. [Miyakis S, et al. J Thromb Haemost. 2006;4: ] [J Thromb Haemost May;12(5):792-5] 15
16 APLA: Risk for 1 st Thrombosis Conclusions: 1. LA stronger and more definitive risk factor for thrombosis than ACA. 2. Risk for thrombosis is highest if positive APLA by multiple assays. [Galli M, et al. Blood. 2003;101: ; Ruffatti A, et al. Thromb Haemost. 2006;96: ] Are APLA a Risk Factor for Recurrent VTE? Systematic Review 8 eligible studies All had important methodologic limitations. We judged the overall quality of the evidence as very low. Conclusion Although it appears that pos. APLA predict d risk of VTE recurrence, the strength of this association is uncertain. [Garcia D et al. Blood 2013;122: ] 16
17 Risk for Recurrent VTE 1. Are APLA a risk factor for recurrent VTE? They appear to be! [Garcia D et al. Blood 2013;122: ] Risk for Recurrent VTE 2. Which of the APLA best predicts recurrent VTE? LA ACA [Garcia D et al. Blood 2013;122: ] 17
18 APLA: Practical Points APLA syndrome : question the diagnosis moderately high titers of ACA ( 40 U/mL) Include anti-β 2 -GP-I antibody testing Test outside the acute event Repeat APLA testing (3 months apart) Know the LA tests and their interpretation Role of IgA antibodies unclear Homocysteine, MTHFR MTHFR C677T, homozygous TT, or A1298C May have higher homocysteine levels Not a risk factor for thrombosis or pregnancy complications Practical point: Don t Test for MTHFR. Practical point: Test for homocysteine? no good indication. MTHFR=methylenetetrahydrofolate reductase [den Heijer MJ. Thromb Haemost. 2005;3: ] [Klerk M. JAMA. 2002;288: ] [Rey E. Lancet. 2003;361: [ACOG Bulletin #124, 2011] 18
19 Factor VIII Factor VIII NOT a useful clinical tool to predict recurrent VTE Arterial thromboembolism 19
20 Unexplained Arterial Thrombosis 1. Arteriosclerosis documented or risk factors present? 2. Cardioembolic source? 3. Other causes (hormones, cocaine, vasculitis, etc?) 4. Thrombophilia? [Moll S. J Thromb Thrombolys 2015; ;39(3):367-78] Arterial Thrombosis FVL: OR 1.21 (95% CI, ) II20210: OR 1.32 (95% CI, OR ) [Kim RJ et al. Am Heart J 2003;146: ] Protein C and S deficiency <55 yrs: 4.7-fold (95 % CI ) >55 yrs: 1.1-fold (95 % CI ) Antithrombin deficiency Not a risk factor Mahmoodi BK, et al. Circulation. 2008;118: ] 20
21 Unexplained Arterial Thrombosis How to best treat (secondary prevention)? 1. Anti-platelet therapy? 2. Anticoagulant? 3. Both together? When to Test? 21
22 Influence of Anticoagulants on Thrombophilia Tests [Moll S. J Thromb Thrombolys 2015;39: ] When To Test $
23 Which Family Members to Test for Thrombophilia Multi-factorial Nature of VTE Fam H/o VTE Thrombophilia (mild, strong ) Hormones Body mass index Smoking What is this ASYMPTOMATIC family member s ABSOLUTE risk for VTE? Previous surgeries, fractures, pregnancies, hormone use WITHOUT VTE [Noboa S, et al. Thromb Res. 2008;122: ] 1. [Bezemer ID, et al. Arch Intern Med. 2009;169: ] 23
24 Which Family Members to Consider for Thrombophilia Screening? Proband s thrombophilia Male Family Member Female Family Member Sons Brothers Daughters Sisters Hetero FVL or hetero prothrombin no no no no Homo FVL or homo prothrombin no reasonable no yes Double hetero reasonable reasonable yes yes C, S, AT reasonable reasonable yes yes Reasonable reasonable because: consider LMWH with airline travel, cast, non-major surgery; prolonged after major surgeries. yes Yes because: advise against estrogen contraceptives/hormone therapy; give anteand postpartum anticoagulation Pregnancy Loss and Other Poor Pregnancy Outcomes 24
25 Pregnancy Loss / Complications [Skeith L et al. Blood 2016;127:1650-5] Pregnancy Loss / Complications All trials Multicenter trials only [Skeith L et al. Blood 2016;127:1650-5] 25
26 1 2 Pregnancy loss + thrombophilia (other than APLA): LMWH treatment NOT indicated. Pregnancy loss: thrombophilia testing NOT indicated (other than APLA) ACOG [Obstet Gynecol 2013 Sep;122(3):706-17] 1 Inherited thrombophilias Testing NOT recommended for recurrent pregnancy loss, placental abruption, IUGR or preeclampsia 2 APLA Testing may be appropriate for women with fetal loss 26
27 My Choosing Wisely Suggestions My Choosing Wisely Suggestions My 15 Choosing Wisely Suggestions a) For health care professionals b) For clinical laboratories c) For hospital systems 27
28 My Choosing Wisely Suggestions Thrombophilia Testing Do NOT test. 1. during an acute thrombotic episode. 2. a hospitalized patient. 3. while patient is on an anticoagulant. 4. if not able to interpret the test or don t know what to do with the results. 28
29 Summary 1 Often little/no evidence of benefit of testing 2 Whom to test? Unexplained unusual venous thrombosis 3. Unexplained arterial clot in the young 3 When to test: NOT acutely, NOT inpatient, NOT on anticoagulation. Summary Inherited and Acquired Thrombophilias Most common Classics Acquired Others Factor V Leiden Prothrombin Protein C deficiency Protein S deficiency Antithrombin deficiency Antiphospholipid antibodies (ACA, LA, anti-β 2 -GPI) Homocysteine, MTHFR Fibrinogen, factor VIII, IX, XI PAI-1, tpa levels and polymorphisms CBC, CD55/59, JAK-2 (exon 12, CALR) 29
30 30
Thrombophilia: To test or not to test
Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationScott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine
Scott M. Stevens, MD Co-Director, Thrombosis Clinic Intermountain Medical Center Associate Professor of Clinical Medicine The University of Utah School of Medicine No Relevant Financial Relationships Research
More informationChoosing Wisely: If, When, What, and Who to Test for Thrombophilia
Choosing Wisely: If, When, What, and Who to Test for Thrombophilia Nicole Dodge Zantek, MD, PhD Medical Director, Special Coagulation Laboratory University of Minnesota Disclosures Financial interests
More informationDISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University
Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)
More informationTHROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO
THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective
More informationGenetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수
Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationLaboratory Evaluation of Venous Thrombosis Risk
Laboratory Evaluation of Venous Thrombosis Risk Dorothy M. Adcock, MD Volume 17, Number 12 December 2003 Objective: The reader will be able to discuss the concepts of risk factor, risk potential and thrombotic
More informationOriginal Policy Date
MP 2.04.71 Genetic Testing for Inherited Thrombophilia Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search12:2013 Return to
More informationConsultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000
Consultative Coagulation How to Effectively Answer Common Questions About Hemostasis Testing Session #5000 Dorothy M. (Adcock) Funk, M.D. Karen A. Moser, M.D. Esoterix Coagulation September 20, 2013 Disclosures
More informationOptimal Utilization of Thrombophilia Testing
Optimal Utilization of Thrombophilia Testing Rajiv K. Pruthi, MBBS Special Coagulation Laboratory & Comprehensive Hemophilia Center Division of Hematology/Internal Medicine Dept of Laboratory Medicine
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Venous Thromboembolism Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic Venous Thromboembolism
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationTHROMBOSIS RISK FACTOR ASSESSMENT
Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationUpdates in Diagnosis & Management of VTE
Updates in Diagnosis & Management of VTE TRACY MINICHIELLO, MD CHIEF, ANTICOAGULATION& THROMBOSIS SERVICE-SAN FRANCISCO VAMC PROFESSOR OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Financial Disclosures-NONE
More informationDuration of anticoagulation
Duration of anticoagulation P. Fontana Service d angiologie et d hémostase Hôpitaux Universitaires de Genève Pomeriggio formativo in coagulazione, Bellinzona, 19.10.2017 Conflict of interest AstraZeneca,
More informationDOACs in SPECIAL POPULATIONS
DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy
More informationThrombophilia testing: who is it good for? F.R. Rosendaal, Leiden
Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden Inaugural meeting of Iranian Society on Thrombosis and Haemostasis Mofid Children Hospital Tehran, 24 December 2015 Chest. 2012;141(2_suppl):e48S-e801S
More informationThrombophilias: A Practical Approach
Disclosures Thrombophilias: A Practical Approach Speaker s Bureau: BMS/Pfizer (Apixaban) PI Altru Health System: EVE Trial Apixaban in Malignancy Keith E Swanson MD North Dakota Family Medicine Conference,
More informationAntiphospholipid Antibody Syndrome: Management Issues for the Hematologist
Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March
More informationTHROMBOPHILIA SCREENING
THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis
More informationPotpourri of Hematology Oncology. Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy
Potpourri of Hematology Oncology Jasmine Nabi, M.D. Oncology Associates Hall-Perrine Cancer Center at Mercy Lifestyle Modifications to Decrease the Risk of Colorectal Cancer Estimates for 2018 American
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationSinus and Cerebral Vein Thrombosis
Sinus and Cerebral Vein Thrombosis A Summary Sinus and cerebral vein clots are uncommon. They can lead to severe headaches, confusion, and stroke-like symptoms. They may lead to bleeding into the surrounding
More informationManifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria
Manifestation of Antiphospholipid Syndrome among Saudi patients :examining the applicability of sapporo Criteria Farjah H AlGahtani Associate professor,md,mph Leukemia,Lymphoma in adolescent,thromboembolic
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationHemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures
Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase
More informationASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation
ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation Stephan Moll Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationLupus Anticoagulants (LA), Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update. Antiphospholipid. Antiphospholipid
, Antiphospholipid (APL) Antibodies & APL Syndrome: Review & Update William L. Nichols, MD Mayo Clinic College of Medicine Rochester, Minnesota USA Disclosures & Objectives (Nichols) Disclosures Relevant
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationStanford University H IGH VALUE C ARE: OPTIMAL A PPROACH. Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD
Stanford University H IGH VALUE C ARE: OPTIMAL A PPROACH TO T HROMBOPHILIA W ORKUPS & FRESH F ROZEN P LASMA U SE Andre Kumar MD Tyler Johnson MD Neil Shah MD Jason Hom MD Learning Objectives AFTER COMPLETION
More informationNew Developments in VTE Treatment
Disclosures: Accommodation at this meeting funded by Boehringer Investigator in phase III studies of Rivaroxiban, Dabigatran, Edoxaban New Developments in VTE Treatment GPCME meeting, August, Dunedin Dr
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationDiagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data COPYRIGHT. Kenneth A.
Diagnosis and Management of Hypercoagulabilty and the Direct Oral Anticoagulants: Interpreting the Data Kenneth A. Bauer, MD kbauer@bidmc.harvard.edu Disclosures Janssen rivaroxaban BMS apixaban Boehringer
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2016 Section: Prescription Drugs
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationPE service. 65 years old lady. What would you do next? Risk stratification. What would you do next? Regional College Lecture PE Management
PE service Regional College Lecture PE Management Update in medicine (Eastern) Cambridge 29 th June 2017 Dr Rachel M Limbrey DM FRCP University Hospital Southampton NHS Foundation Trust Ambulatory acute
More informationThrombophilia. Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS
Autoimmune Thrombophilia Dr. A Sarrafnejad PhD Dep. Immunology School of public health TUMS Saraf@sina.tums.ac.ir Acquired Thrombophilia HIT PNH Cyckle cell Anemia Myeloproliferative lf Diseases Thrombocytosis
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationThrombosis. By Dr. Sara Mohamed Abuelgasim
Thrombosis By Dr. Sara Mohamed Abuelgasim 1 Thrombosis Unchecked, blood coagulation would lead to dangerous occlusion of blood vessels if the protective mechanisms of coagulation factor inhibitors, blood
More informationIs Thrombophilia Testing Useful?
CONSULTATIVE HEMATOLOGY I: COMMON QUESTIONS IN THROMBOSIS CONSULTS Is Thrombophilia Testing Useful? Saskia Middeldorp 1 1 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
More informationDiagnosis and management of heritable thrombophilias
Link to this article online for CPD/CME credits Diagnosis and management of heritable thrombophilias Peter MacCallum, 1 2 Louise Bowles, 2 David Keeling 3 1 Wolfson Institute of Preventive Medicine, Barts
More informationRisk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD
Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationVenous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD
Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationAntiphospholipid antibodies
CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE Antiphospholipid Antibodies Caron P. Misita, PharmD; Stephan Moll, MD Antiphospholipid antibodies (APLAs) are proteins that may be present in the blood and
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: None Genetic Testing for Inherited Thrombophilia Description Inherited thrombophilias are a group of disorders that predispose
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More informationDuration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,
More informationSindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy
Sindrome da anticorpi antifosfolipidi: clinica e terapia Vittorio Pengo Clinical Cardiology, Padova, Italy Revised Classification Criteria for the Antiphospholipid Syndrome J Thromb Haemost 2006;4:295-306
More informationMohammadreza Tabatabaei IBTO COAG LAB
Tests for the Evaluation of Lupus Anticoagulants t Mohammadreza Tabatabaei MSc Hematology blood bank MSc Hematology blood bank IBTO COAG LAB Lupus Anticoagulants General Background Lupus anticoagulants
More informationDave Duddleston, MD VP and Medical Director Southern Farm Bureau Life
Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic
More informationCitation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. [Groningen]: Rijksuniversiteit Groningen.
University of Groningen The pill and thrombosis van Vlijmen, Elizabeth Femma Willemien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationVenous Thromboembolic Disease Update
Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationHomocysteine is a chemical in
CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE Homocysteine and MTHFR Mutations Relation to Thrombosis and Coronary Artery Disease Elizabeth A. Varga, MS; Amy C. Sturm, MS; Caron P. Misita, PharmD; Stephan
More informationPredicting the risk of recurrent venous thromboembolism (VTE)
J Thromb Thrombolysis (2015) 39:353 366 DOI 10.1007/s19-015-1188-4 Predicting the risk of recurrent venous thromboembolism (VTE) Michael B. Streiff Published online: 27 February 2015 Ó Springer Science+Business
More informationTop Ten Reasons For Failure To Prevent Postoperative Thrombosis
Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Joseph A. Caprini, MD, MS, FACS, RVT, FACCWS Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical
More informationWGA meeting Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège
WGA meeting 2016 Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège Clinical question Which complementary investigations are you going to plan during or early after hospitalization
More informationShould Patients with Venous Thromboembolism Be Screened for Thrombophilia?
REVIEW Should Patients with Venous Thromboembolism Be Screened for Thrombophilia? James E. Dalen, MD, MPH University of Arizona, Tucson. ABSTRACT In the mid-19th century, Virchow identified hypercoagulability
More informationVenous Thromboembolism: Principles of Outpatient and Inpatient Management
Venous Thromboembolism: Principles of Outpatient and Inpatient Management August 1, 2017 Seth Maliske, M.D. Internal Medicine Aspirus Wausau Hospital Disclosures/Conflicts of Interest I have no financial
More informationAbsence of the Factor V Leiden mutation and genetic risk for CTEPH
Absence of the Factor V Leiden mutation and genetic risk for CTEPH Mark W. Dodson, MD, PhD Assistant Professor, Pulmonary/Critical Care Intermountain Medical Center Murray, Utah A paradox in our current
More informationChapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families
Chapter A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Willem M. Lijfering Nic J.G.M. Veeger Saskia Middeldorp Karly Hamulyák Martin
More informationThe Antiphospholipid Syndrome
The Antiphospholipid Syndrome 1 / 6 2 / 6 3 / 6 The Antiphospholipid Syndrome Antiphospholipid antibody syndrome (commonly called antiphospholipid syndrome or APS) is an autoimmune disease present mostly
More informationAnticoagulant Therapy During Pregnancy
Anticoagulant Therapy During Pregnancy AIM - June 2007 Russell K. Laros, Jr., MD Thromboembolism and Pregnancy Leading Non-Obstetrical Cause of Maternal Mortality Early recognition and proper treatment
More informationSpontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker
More informationFaculty Disclosure. Hypercoagulable States. Learning Objectives. Hereditary Thombophilia. Acquired Hypercoagulable States 5/9/2016
Faculty Disclosure Hypercoagulable States Dr. Rizal has no actual or potential conflict of interest associated with this presentation By: Dr. Anuja Rizal Pharm. D., RPh., CACP Clinical Coordinator UConn
More informationEpidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione
Epidemiologia e clinica del tromboembolismo venoso Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Thrombophilia may present clinically as one or more of several thrombotic manifestations
More informationVenous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017
Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in
More informationKeep catheter. Anticoagulate. Yes. Symptoms resolved? Yes. No Catheter needed? Other access sites available? Yes. Anticoagulate. Place new catheter
Chief Anticoagulation and Thrombosis Service UCSF, SF VA MED CTR Thromboembolism Q&A Management of the Hospitalized Patient, SF, CA October 2012 CASES & ANSWERS 1. A 55 year old woman being treated for
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationVenous thromboembolism (VTE) consists of deep vein
Clinical Utility of Factor V Leiden (R506Q) Testing for the Diagnosis and Management of Thromboembolic Disorders Richard D. Press, MD, PhD; Kenneth A. Bauer, MD; Jody L. Kujovich, MD; John A. Heit, MD
More informationCOAGULATIONS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin)
COAGULATIONS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin) Haemostasis-blood must be maintained in a fluid state in order to function as a transport system, but must be able to solidify to form a clot following
More informationThrombophilia: 2009 Update Pat Foy, MD Stephan Moll, MD
Thrombophilia: 2009 Update Pat Foy, MD Stephan Moll, MD Corresponding author Stephan Moll, MD Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of Medicine, CB7035,
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationThis chapter will describe the effectiveness of antithrombotic
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,
More informationVenous thromboembolism (VTe) affects approximately
The Journal of The american osteopathic association Duration of Anticoagulation Treatment in Patients With Venous Thromboembolism Scott Kaatz, DO, MSc; Waqas Qureshi, MD; Christopher Fain, DO; and David
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationMolecular mechanisms & clinical consequences. of prothrombin mutations. A.J. Hauer
Molecular mechanisms & clinical consequences of prothrombin mutations A.J. Hauer 07-12-2018 Prothrombin & the coagulation cascade Coagulation factor II, thrombin. Prothrombin is synthesized in the liver
More informationVenous Thrombosis in Asia
Venous Thrombosis in Asia Pantep Angchaisuksiri, M.D. Professor of Medicine, Mahidol University, Thailand Adjunct Associate Professor, University of North Carolina, Chapel Hill, USA Venous Thromboembolism
More informationThursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III
REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels
More informationAnticoagulation Forum: Management of Tiny Clots
Anticoagulation Forum: Management of Tiny Clots Casey O Connell, MD FACP Associate Professor Jane Anne Nohl Division of Hematology Keck School of Medicine USC DISCLOSURES None 4/11/2017 Objectives Define
More informationAnticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!)
Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!) Clinical Learning Day 2017 Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain
More informationThrombophilia testing in patients with venous thrombosis
Thrombophilia testing in patients with venous thrombosis Joseph A. Caprini, MD, Sofia Goldshteyn, MD, Catherine J. Glase, BS, Karen Hathaway, BS, Evanston and Chicago, IL. Department of Surgery Evanston
More informationVenous thrombosis in unusual sites
Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers
More informationVascular Protection: Preventing Thrombotic Complications of VTE and PAD
Vascular Protection: Preventing Thrombotic Complications of VTE and PAD Thursday, October 11, 2018, 2:00pm ET Guest Speakers: Geoff Barnes, MD Scott Damrauer, MD Moderators: Tracy Minichiello, MD; Sara
More informationInteractive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome)
Interactive Case Vignette: DOACs (Direct Oral Anti-Coagulants) vs. Warfarin for APLA (Anti-Phospholipid Antibody Syndrome) Ara Metjian, MD Duke Debates Benign Hematologic Highlights April 22, 2017 Disclaimer
More informationAdaptation of Published Heritable Thrombophilia Testing Guidelines into Local Practice
Adaptation of Published Heritable Thrombophilia Testing Guidelines into Local Practice Tyler Smith, PGY-5, UBC Hematopathology Supervisor: Dr. A. Lee Collaborators: Dr. D. Pi, Dr. M. Hudoba 2011 CADTH
More information